调强放疗再程治疗复发或第二原发头颈癌的荟萃分析与系统综述
该系统综述纳入17项研究共1635例复发或第二原发头颈癌患者,评估IMRT再程放疗的疗效与毒性。汇总2年局部控制率为52%(95%CI 46%-57%),2年总生存率为46%(95%CI 41%-50%)。
要点
- IMRT再程放疗汇总2年局部控制率52%、总生存率46%。
- 补救手术比例≥42%者2年局部控制率更高(58.5% vs 45.9%)。
- 晚期≥3级毒性26%,5级毒性3.1%。
核心结论
- 与IMRT前时代的历史结局相比,IMRT再程放疗是有效的治疗方式。
研究设计与样本
- 系统综述与荟萃分析,纳入17项研究共1635例复发或第二原发头颈癌患者。
- 排除仅涉及复发鼻咽癌患者的研究。
主要发现
- 汇总2年局部控制率为52%(95%CI 46%-57%)。
- 汇总2年总生存率为46%(95%CI 41%-50%)。
- 晚期≥3级毒性汇总率为26%(95%CI 20%-32%)。
- 5级毒性汇总率为3.1%(95%CI 2%-5%)。
临床怎么用
- 对于复发或第二原发头颈癌,IMRT再程放疗可作为有效治疗选择,需关注晚期毒性。
- 补救手术比例较低(<42%)的患者再程IMRT的局部控制可能较差。
局限性
- 多数纳入研究为回顾性(82%)且来自单中心(88%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To summarize outcomes of reirradiation with intensity-modulated radiotherapy (IMRT) for recurrent or secondary head and neck cancer (HNC). METHODS: Primary endpoints were 2-year local control (LC) and overall survival (OS). Studies involving only recurrent nasopharyngeal patients with cancer were excluded. RESULTS: A total of 17 studies involving 1635 patients were included. Fourteen (82%) of those were retrospective, and 15 (88%) were from single institution. Reirradiation with IMRT produced pooled 2-year LC and OS rates of 52% (95% confidence interval [CI], 46%-57%) and 46% (95% CI, 41%-50%), respectively. In subgroup analyses, the rate of salvage surgery (<42% vs ≥42%) influenced the pooled 2-year LC rate (45.9% vs 58.5%, P = .011). The pooled rates of late grade ≥ 3 and grade 5 toxicities were 26% (95% CI, 20%-32%) and 3.1% (95% CI, 2%-5%), respectively. CONCLUSIONS: Reirradiation with IMRT was an effective modality compared to historical outcomes in the pre-IMRT era.
引用
- Lee J, Shin IS, Kim WC, et al. Reirradiation with intensity-modulated radiation therapy for recurrent or secondary head and neck cancer: Meta-analysis and systematic review. Head Neck. 2020. PMID: 32437021. doi:10.1002/hed.26264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。